Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 24 Sep 2026 · Editorial standards

Gemcitabine is named as a drug or biological intervention in 207 clinical trials in our China, USA, UK, Ireland and India trial registers, 98 of which are recruiting. Lead sponsors include AstraZeneca (17), Sun Yat-sen University (15) and Merck Sharp & Dohme LLC (10). Registered phases: Phase 3, Phase 2, Phase 1/2, Phase 1, Phase 2/3, Not applicable and Observational. Conditions studied include Pancreatic Cancer; Nasopharyngeal Carcinoma; Pancreatic Ductal Adenocarcinoma.

Clinical trials of Gemcitabine

207 trials

NCT ID	Study	Phase	Status	Lead sponsor	Register
NCT03257033	Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (ClinicalTrials.gov ↗) Locally Advanced Pancreatic Cancer	Phase 3	Recruiting	RenovoRx	USA
NCT05302284	A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma (ClinicalTrials.gov ↗) Urothelial Carcinoma, HER2-expressing	Phase 3	Recruiting	RemeGen Co., Ltd.	China
NCT05854849	Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
NCT06103864	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) (ClinicalTrials.gov ↗) Breast Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
NCT06170489	A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) (ClinicalTrials.gov ↗) Hodgkin Lymphoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
NCT06239727	Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
NCT06282575	Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer	Phase 3	Recruiting	Jazz Pharmaceuticals	UK, USA, India, China
NCT06312137	A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (ClinicalTrials.gov ↗) Non Small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
NCT06319820	A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer Non-Muscle Invasive Bladder Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	Ireland, UK, USA, China
NCT06435429	A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Metastatic HER2-positive Breast Cancer	Phase 3	Recruiting	Jazz Pharmaceuticals	UK, USA
NCT06467357	Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
NCT06522737	A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype (ClinicalTrials.gov ↗) Lymphoma	Phase 3	Recruiting	SecuraBio	UK
NCT06592326	9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer (ClinicalTrials.gov ↗) Urothelial Carcinoma	Phase 3	Recruiting	Mabwell (Shanghai) Bioscience Co., Ltd.	China
NCT06623422	A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
NCT06841354	A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (ClinicalTrials.gov ↗) Triple Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
NCT06919965	A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer Non-Muscle Invasive Bladder Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, China
NCT07079228	A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd.	China
NCT07173751	ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (ClinicalTrials.gov ↗) Breast Neoplasms	Phase 3	Recruiting	BioNTech SE	UK, USA, China
NCT07213804	A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms	Phase 3	Recruiting	Eli Lilly and Company	Ireland, UK, USA, China
NCT07436741	Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, Adult	Phase 3	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
NCT07459296	Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma (NPC)	Phase 3	Recruiting	First Affiliated Hospital of Guangxi Medical University	China
NCT07461454	YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (ClinicalTrials.gov ↗) Locally Advanced or Metastatic Breast Cancer	Phase 3	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	China
NCT07491445	Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (ClinicalTrials.gov ↗) Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc.	UK, USA, China
NCT07564141	Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer (ClinicalTrials.gov ↗) Platinum-Sensitive Ovarian Cancer, Ovarian Cancer	Phase 3	Recruiting	Genmab	USA
NCT07566156	Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) (ClinicalTrials.gov ↗) Urothelial Cancer, Urinary Bladder Neoplasms	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	USA
NCT07570823	A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗) DLBCL - Diffuse Large B Cell Lymphoma	Phase 3	Recruiting	Sinocelltech Ltd.	China
NCT07604766	An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China (ClinicalTrials.gov ↗) Platinum-resistant Ovarian Cancer	Phase 3	Recruiting	Genmab	China
NCT07621718	Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) (ClinicalTrials.gov ↗) Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc.	USA
NCT07693959	Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC (ClinicalTrials.gov ↗) MIBC	Phase 3	Recruiting	Zhiquan Hu	China
NCT07805954	Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc.	USA
NCT05139017	A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (ClinicalTrials.gov ↗) DLBCL, Diffuse Large B-Cell Lymphoma	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
NCT05254171	Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV	Phase 2/3	Recruiting	Panbela Therapeutics, Inc.	UK, USA
NCT06493552	Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors (ClinicalTrials.gov ↗) Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma	Phase 2/3	Recruiting	Vasgene Therapeutics, Inc	USA
NCT06926868	A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) (ClinicalTrials.gov ↗) Breast Neoplasms	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
NCT07106762	Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy (ClinicalTrials.gov ↗) Urothelial Cancer	Phase 2/3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China
NCT07129993	Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (ClinicalTrials.gov ↗) Urothelial Cancer, Bladder Cancer	Phase 2/3	Recruiting	Daiichi Sankyo	USA, China
NCT03498326	Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, Chemotherapy Effect	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
NCT05859750	A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 2	Recruiting	Akeso	China
NCT05934331	A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study (ClinicalTrials.gov ↗) Malignant Neoplasms of Digestive Organs	Phase 2	Recruiting	LaNova Medicines Zhejiang Co., Ltd.	China
NCT05943379	RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects NMIBC	Phase 2	Recruiting	RemeGen Co., Ltd.	China
NCT05999994	A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (ClinicalTrials.gov ↗) Neoplasms, Child, Adolescent	Phase 2	Recruiting	Eli Lilly and Company	UK, USA
NCT06102824	Organoid-based Functional Precision Therapy for Advanced Breast Cancer (ClinicalTrials.gov ↗) HER2-negative Breast Cancer, Advanced Breast Cancer	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
NCT06219941	AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China
NCT06255210	Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) (ClinicalTrials.gov ↗) Olfactory Neuroblastoma	Phase 2	Recruiting	Hongmeng Yu	China
NCT06261359	A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma (ClinicalTrials.gov ↗) Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 2	Recruiting	Qilu Pharmaceutical Co., Ltd.	China
NCT06323239	SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
NCT06359275	PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 2	Recruiting	Fudan University	China
NCT06421298	A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. (ClinicalTrials.gov ↗) Lung Cancer	Phase 2	Recruiting	Jinghui Wang	China
NCT06491472	Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
NCT06708858	Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer (ClinicalTrials.gov ↗) Advanced Biliary Tract Cancer	Phase 2	Recruiting	Dai, Guanghai	China
NCT06710288	A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (ClinicalTrials.gov ↗) Platinum-resistant Ovarian Cancer	Phase 2	Recruiting	ImmunityBio, Inc.	USA
NCT06721286	Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma (ClinicalTrials.gov ↗) Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
NCT06770439	IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer (ClinicalTrials.gov ↗) Advanced Pancreatic Cancers	Phase 2	Recruiting	Zhejiang University	China
NCT06770452	HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients Metastatic Pancreatic Carcinoma	Phase 2	Recruiting	Zhejiang University	China
NCT06788912	Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) (ClinicalTrials.gov ↗) Lung Neoplasm Malignant	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA
NCT06806033	Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL (ClinicalTrials.gov ↗) Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma	Phase 2	Recruiting	Hoffmann-La Roche	USA
NCT06851247	GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma. (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
NCT06904573	Probiotics in Advanced Urothelial Carcinoma (ClinicalTrials.gov ↗) Advanced Urothelial Carcinoma, Probiotics, Immunotherapy	Phase 2	Recruiting	Sun Yat-sen University	China
NCT06951997	QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer (ClinicalTrials.gov ↗) Metastatic Pancreatic Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
NCT07007559	ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer, Metastatic	Phase 2	Recruiting	ALX Oncology Inc.	UK, USA
NCT07099547	Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma (ClinicalTrials.gov ↗) Biliary Tract Carcinoma	Phase 2	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
NCT07296705	Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC (ClinicalTrials.gov ↗) Muscle Invasive Bladder Cancer (MIBC)	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
NCT07359053	MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma (ClinicalTrials.gov ↗) Sarcoma	Phase 2	Recruiting	Shanghai 6th People's Hospital	China
NCT07492680	A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) Solid Tumors	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, USA, China
NCT07569679	Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer	Phase 2	Recruiting	Air Force Military Medical University, China	China
NCT07668453	An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies (ClinicalTrials.gov ↗) Biliary Tract Neoplasms	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
NCT07741448	Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC (ClinicalTrials.gov ↗) UTUC	Phase 2	Recruiting	Zhiquan Hu	China
NCT07769502	A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers (ClinicalTrials.gov ↗) Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma	Phase 2	Recruiting	AbbVie	China
NCT07831993	Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
NCT04198766	Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (ClinicalTrials.gov ↗) Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer	Phase 1/2	Recruiting	Inhibrx Biosciences, Inc	USA
NCT04495296	A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗) Advanced Cancer	Phase 1/2	Recruiting	Transcenta Therapeutics (Hangzhou) Co., Ltd.	China
NCT04657068	A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗) Advanced Cancer, Metastatic Cancer, Ovarian Cancer	Phase 1/2	Recruiting	Artios Pharma Ltd	UK, USA
NCT05218889	Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer	Phase 1/2	Recruiting	Chinese PLA General Hospital	China
NCT05431270	Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) (ClinicalTrials.gov ↗) Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Phanes Therapeutics	USA
NCT05482893	Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) (ClinicalTrials.gov ↗) Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
NCT05786924	Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis	Phase 1/2	Recruiting	Institut de Recherches Internationales Servier	China
NCT06445062	Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (ClinicalTrials.gov ↗) Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Revolution Medicines, Inc.	USA
NCT06741644	A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China
NCT06843447	A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (ClinicalTrials.gov ↗) Ovarian Cancer Recurrent	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA
NCT07020221	A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors (ClinicalTrials.gov ↗) Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer	Phase 1/2	Recruiting	Verastem, Inc.	USA
NCT07049055	A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Engeneic Pty Limited	USA
NCT07124936	A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗) Diffuse Large B Cell Lymphoma (DLBCL)	Phase 1/2	Recruiting	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	China
NCT07223047	A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies (ClinicalTrials.gov ↗) Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Recruiting	Bristol-Myers Squibb	USA
NCT07235202	A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy (ClinicalTrials.gov ↗) Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 1/2	Recruiting	Shenzhen Majory Biotechnology Co., Ltd.	China
NCT07296341	HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors (ClinicalTrials.gov ↗) Locally Advanced or Metastatic Pancreatic Cancer With	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT07444541	ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 1/2	Recruiting	Anova Innovation Limited	USA
NCT04516447	A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer (ClinicalTrials.gov ↗) Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer	Phase 1	Recruiting	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	USA
NCT05382559	A Study of ASP3082 in Adults With Advanced Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China
NCT06181032	A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies (ClinicalTrials.gov ↗) Biliary Tract Malignancies	Phase 1	Recruiting	First Affiliated Hospital of Fujian Medical University	China
NCT06586515	MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Recruiting	Eli Lilly and Company	Ireland, USA, China
NCT06624085	A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗) Lymphoma	Phase 1	Recruiting	Hoffmann-La Roche	USA
NCT06886347	Metastatic Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Metastatic Nasopharyngeal Carcinoma	Phase 1	Recruiting	Chen Xiaozhong	China
NCT06917079	BBO-11818 in Adult Subjects With KRAS Mutant Cancer (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA
NCT07024615	A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc.	USA
NCT07640048	Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study (ClinicalTrials.gov ↗) Intrahepatic Cholangiocarcinoma (Icc)	Observational	Recruiting	Peking Union Medical College Hospital	China
NCT05352321	Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Not applicable	Recruiting	Sun Yat-sen University	China
NCT05717790	Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma by AJCC V8 Stage	Not applicable	Recruiting	Fourth Affiliated Hospital of Guangxi Medical University	China
NCT06611345	A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers (ClinicalTrials.gov ↗) Biliary Tract Cancers (BTC)	Not applicable	Recruiting	Jiangsu Healthy Life Innovation Medical Technology Co., Ltd	China
NCT06217042	HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 3	Not yet open	Fudan University	China
NCT07272109	Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 3	Not yet open	Fudan University	China
NCT07383922	A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 3	Not yet open	FutureGen Biopharmaceutical (Beijing) Co., Ltd	China
NCT07445295	Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (ClinicalTrials.gov ↗) Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Not yet open	Chipscreen Biosciences, Ltd.	China
NCT07540390	GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Not yet open	Sun Yat-sen University	China
NCT07691515	Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (ClinicalTrials.gov ↗) Intrahepatic Cholangiocarcinoma (Icc)	Phase 3	Not yet open	Zhejiang Cancer Hospital	China
NCT07783321	A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) Nasopharyngeal Carcinoma (NPC)	Phase 3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd.	China
NCT07797153	JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer (ClinicalTrials.gov ↗) Recurrent or Metastatic Cervical Cancer	Phase 3	Not yet open	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
NCT07821606	Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer (ClinicalTrials.gov ↗) Platinum-sensitive Recurrent Ovarian Cancer	Phase 3	Not yet open	Hansoh BioMedical R&D Company	China
NCT04890522	An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma, Metastasis, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
NCT05988372	Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) (ClinicalTrials.gov ↗) Locally Advanced Pancreatic Cancer	Phase 2	Not yet open	Sun Yat-sen University	China
NCT06177522	Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, Neoadjuvant Therapy	Phase 2	Not yet open	Jinling Hospital, China	China
NCT06234072	Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 2	Not yet open	Shenzhen University General Hospital	China
NCT06361030	Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC	Phase 2	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
NCT06446388	Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor	Phase 2	Not yet open	Qilu Pharmaceutical Co., Ltd.	China
NCT06621095	Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) (ClinicalTrials.gov ↗) Pancreatic Cancer, First-line, Metastatic Pancreatic Cancer	Phase 2	Not yet open	RenJi Hospital	China
NCT07189793	Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study (ClinicalTrials.gov ↗) Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder	Phase 2	Not yet open	First Affiliated Hospital of Wenzhou Medical University	China
NCT07328802	Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma (ClinicalTrials.gov ↗) ORR,OS,PFS	Phase 2	Not yet open	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
NCT07554482	Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma (ClinicalTrials.gov ↗) Extranodal NK/T-cell Lymphoma	Phase 2	Not yet open	Beijing Tongren Hospital	China
NCT07768943	GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma (ClinicalTrials.gov ↗) Natural Killer/T-cell Lymphoma	Phase 2	Not yet open	Fudan University	China
NCT07776171	Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer (ClinicalTrials.gov ↗) Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)	Phase 2	Not yet open	Sun Yat-sen University	China
NCT07797881	A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma (NPC)	Phase 2	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd.	China
NCT07824856	Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases	Phase 2	Not yet open	Sun Yat-sen University	China
NCT07828756	Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
NCT06370754	Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 1/2	Not yet open	Fudan University	China
NCT06888674	Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. (ClinicalTrials.gov ↗) Pancreatic Cancer Resectable	Phase 1/2	Not yet open	Zhejiang University	China
NCT07678593	A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (ClinicalTrials.gov ↗) Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation	Phase 1/2	Not yet open	Genfleet Therapeutics (Shanghai) Inc.	China
NCT07802184	GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC (ClinicalTrials.gov ↗) Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer	Phase 1/2	Not yet open	West China Hospital	China
NCT07699757	HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors	Phase 1	Not yet open	Haisco Pharmaceutical Group Co., Ltd.	China
NCT05903703	Canagliflozin With Gemcitabine in Pancreatic Carcinoma (ClinicalTrials.gov ↗) Pancreatic Cancer	Not applicable	Not yet open	Zhang Xiaofeng,MD	China
NCT05947825	Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients (ClinicalTrials.gov ↗) PDAC - Pancreatic Ductal Adenocarcinoma	Phase 2	By invitation	Tianjin Medical University Cancer Institute and Hospital	China
NCT07353294	Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC (ClinicalTrials.gov ↗) Bladder Urothelial Carcinoma, Lymph Node Metastasis	Phase 1	By invitation	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
NCT06883136	Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer	Observational	By invitation	Qianfoshan Hospital	China
NCT02453282	Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (ClinicalTrials.gov ↗) Non-Small-Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA
NCT02460887	The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
NCT02486718	Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
NCT02516241	Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer (ClinicalTrials.gov ↗) Urothelial Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China
NCT02542293	Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
NCT03003962	Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA, China
NCT03017326	Paediatric Hepatic International Tumour Trial (ClinicalTrials.gov ↗) Hepatoblastoma, Carcinoma, Hepatocellular	Phase 3	Active, closed	University of Birmingham	Ireland
NCT03036098	Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (ClinicalTrials.gov ↗) Urothelial Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	USA, China
NCT03164616	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (ClinicalTrials.gov ↗) Non Small Cell Lung Cancer NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, China
NCT03425643	Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
NCT03456076	A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗) Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
NCT03682068	Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (ClinicalTrials.gov ↗) Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China
NCT03732677	Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC Muscle Invasive Bladder Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA
NCT03734029	Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (ClinicalTrials.gov ↗) Breast Cancer	Phase 3	Active, closed	Daiichi Sankyo	UK, USA, China
NCT03800134	A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China
NCT04223856	Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (ClinicalTrials.gov ↗) Urothelial Cancer	Phase 3	Active, closed	Astellas Pharma Global Development, Inc.	UK, USA, China
NCT04241185	Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) (ClinicalTrials.gov ↗) Urinary Bladder Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA
NCT04384484	Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗) Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	ADC Therapeutics S.A.	UK, USA, China
NCT04408638	A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗) Diffuse Large B-cell Lymphoma	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
NCT04639986	Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (ClinicalTrials.gov ↗) Metastatic Breast Cancer	Phase 3	Active, closed	Gilead Sciences	China
NCT04658862	A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (ClinicalTrials.gov ↗) Urinary Bladder Neoplasms	Phase 3	Active, closed	Janssen Research & Development, LLC	USA, India, China
NCT04700124	Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (ClinicalTrials.gov ↗) Bladder Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
NCT04907370	PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
NCT05104866	A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
NCT05171647	A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (ClinicalTrials.gov ↗) Non-Hodgkin Lymphoma	Phase 3	Active, closed	Hoffmann-La Roche	USA, China
NCT05294172	KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma, Recurrent or Metastatic	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
NCT05382286	Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ClinicalTrials.gov ↗) Triple Negative Breast Cancer, PD-L1 Positive	Phase 3	Active, closed	Gilead Sciences	UK, USA
NCT05382299	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ClinicalTrials.gov ↗) Triple Negative Breast Cancer, PD-L1 Negative	Phase 3	Active, closed	Gilead Sciences	UK, USA, China
NCT05587374	Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma, Nasopharyngeal Cancer	Phase 3	Active, closed	Sun Yat-sen University	China
NCT05771480	Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (ClinicalTrials.gov ↗) Biliary Tract Cancer	Phase 3	Active, closed	AstraZeneca	USA
NCT05911295	Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 (ClinicalTrials.gov ↗) Urothelial Carcinoma	Phase 3	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China
NCT06118333	A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd.	China
NCT06211764	A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (ClinicalTrials.gov ↗) Non-Muscle Invasive Bladder Neoplasms	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China
NCT06343948	A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) (ClinicalTrials.gov ↗) HR+HER2- Breast Cancer	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd.	China
NCT06459180	A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) Cervical Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
NCT06508658	A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗) Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Genmab	UK, USA, China
NCT06519370	FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (ClinicalTrials.gov ↗) Triple Negative Breast Cancer	Phase 3	Active, closed	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	China
NCT06608927	Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (ClinicalTrials.gov ↗) Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Active, closed	Arcus Biosciences, Inc.	UK, USA
NCT06619236	Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (ClinicalTrials.gov ↗) Platinum-resistant Ovarian Cancer	Phase 3	Active, closed	Genmab	USA, China
NCT06625320	Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (ClinicalTrials.gov ↗) Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 3	Active, closed	Revolution Medicines, Inc.	USA
NCT06629597	A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Active, closed	MediLink Therapeutics (Suzhou) Co., Ltd.	China
NCT06935409	Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure (ClinicalTrials.gov ↗) Osteosarcoma	Phase 3	Active, closed	Hansoh BioMedical R&D Company	China
NCT02641847	TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature (ClinicalTrials.gov ↗) Triple Negative Breast Cancer, Breast Cancer	Phase 2/3	Active, closed	Fudan University	China
NCT02867865	Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Gall Bladder Cancers	Phase 2/3	Active, closed	Tata Memorial Hospital	India
NCT03178552	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) Non-Small Cell Lung Cancer	Phase 2/3	Active, closed	Hoffmann-La Roche	USA, China
NCT04442022	A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (ClinicalTrials.gov ↗) Relapsed/Refractory Diffuse Large B-cell Lymphoma	Phase 2/3	Active, closed	Karyopharm Therapeutics Inc	USA, China
NCT07076121	A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) Pancreatic Ductal Adenocarcinoma	Phase 2/3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, India, China
NCT02340117	Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer (ClinicalTrials.gov ↗) Metastatic Pancreatic Cancer	Phase 2	Active, closed	SynerGene Therapeutics, Inc.	USA
NCT02711553	A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer	Phase 2	Active, closed	Eli Lilly and Company	UK, USA, China
NCT03547973	Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (ClinicalTrials.gov ↗) Metastatic Urothelial Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA
NCT03775486	Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) Non-small Cell Lung Cancer NSCLC	Phase 2	Active, closed	AstraZeneca	UK, USA, India
NCT03816163	A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma	Phase 2	Active, closed	Astellas Pharma Global Development, Inc.	Ireland, USA, China
NCT04999969	Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours (ClinicalTrials.gov ↗) Locally Advanced or Metastatic Solid Tumours	Phase 2	Active, closed	AstraZeneca	USA
NCT05026905	A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer (ClinicalTrials.gov ↗) Phase II, Open-label, Parallel 2-arm, Multi-center	Phase 2	Active, closed	National Health Research Institutes, Taiwan	China
NCT05524168	SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
NCT05775159	Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (ClinicalTrials.gov ↗) Hepatocellular Carcinoma, Biliary Tract Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China
NCT05813626	Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 2	Active, closed	Zhejiang Cancer Hospital	China
NCT06225596	Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (ClinicalTrials.gov ↗) Metastatic Urothelial Cancer	Phase 2	Active, closed	BicycleTx Limited	UK, USA, China
NCT06313970	First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 2	Active, closed	Fudan University	China
NCT06449222	Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (ClinicalTrials.gov ↗) Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers	Phase 2	Active, closed	BioNTech SE	UK, USA
NCT06465563	SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT06492915	Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (ClinicalTrials.gov ↗) Pancreatic Ductal Adenocarcinoma	Phase 2	Active, closed	Chipscreen Biosciences, Ltd.	China
NCT06632951	Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) Urothelial Carcinoma	Phase 2	Active, closed	AbbVie	USA
NCT07005336	A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Non Small Cell Lung Cancer	Phase 2	Active, closed	TJ Biopharma Co., Ltd.	China
NCT07806110	Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreas Ductal Adenocarcinoma	Phase 2	Active, closed	The First Hospital of Jilin University	China
NCT04083599	GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Active, closed	Genmab	UK, USA, China
NCT04396821	A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer	Phase 1/2	Active, closed	Transcenta Therapeutics (Hangzhou) Co., Ltd.	USA
NCT05141149	First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 1/2	Active, closed	Prestige Biopharma Limited	USA
NCT05229497	A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors (ClinicalTrials.gov ↗) Advanced Malignant Tumors	Phase 1/2	Active, closed	Akeso	China
NCT02937272	A Study of LY3200882 in Participants With Solid Tumors Solid Tumor	Phase 1	Active, closed	Eli Lilly and Company	USA
NCT03819465	A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Active, closed	AstraZeneca	USA
NCT03872947	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor, Colorectal Cancer, Cholangiocarcinoma	Phase 1	Active, closed	Toray Industries, Inc	USA
NCT04521686	Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Cholangiocarcinoma, Chondrosarcoma, Glioma	Phase 1	Active, closed	Eli Lilly and Company	USA, China
NCT04947241	Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC (ClinicalTrials.gov ↗) Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy	Phase 1	Active, closed	Fifth Affiliated Hospital, Sun Yat-Sen University	China
NCT06360354	A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) (ClinicalTrials.gov ↗) Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers	Phase 1	Active, closed	Amgen	UK, USA, China
NCT06607185	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (ClinicalTrials.gov ↗) Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied

172 conditions

Condition (as registered)	Trials
Pancreatic Cancer	25
Nasopharyngeal Carcinoma	16
Pancreatic Ductal Adenocarcinoma	13
Biliary Tract Cancer	9
PDAC - Pancreatic Ductal Adenocarcinoma	8
Non-Small Cell Lung Cancer	7
Urothelial Cancer	6
Metastatic Pancreatic Cancer	5
Colorectal Cancer	5
Triple Negative Breast Cancer	5
PDAC	5
Solid Tumor	5
Non-small Cell Lung Cancer	4
Urothelial Carcinoma	4
Breast Cancer	4
Pancreatic Cancer Metastatic	4
Advanced Cancer	4
Non Small Cell Lung Cancer	4
Urinary Bladder Neoplasms	4
Non-Muscle Invasive Bladder Neoplasms	3
Metastatic Urothelial Cancer	3
Ovarian Cancer	3
Bladder Cancer	3
Platinum-resistant Ovarian Cancer	3
Pancreatic Ductal Adenocarcinoma (PDAC)	3
Locally Advanced Pancreatic Cancer	3
Nasopharyngeal Carcinoma (NPC)	3
Intrahepatic Cholangiocarcinoma (Icc)	3
Neoplasm Metastasis	2
Carcinoma, Non-Small-Cell Lung	2
Gastric Cancer	2
Colorectal Cancer (CRC)	2
Melanoma	2
Breast Neoplasms	2
Metastatic Cancer	2
Non Small Cell Lung Carcinoma NSCLC	2
Lymphoma	2
Diffuse Large B-Cell Lymphoma	2
Metastatic Pancreatic Ductal Adenocarcinoma	2
Cholangiocarcinoma	2

+ 132 more conditions in the trial records above.

Trials by country register

Register	Gemcitabine trials
Clinical trials in China	158
Clinical trials in USA	100
Clinical trials in UK	52
Clinical trials in Ireland	12
Clinical trials in India	12

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gemcitabine works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gemcitabine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Gemcitabine

Clinical trials of Gemcitabine

Conditions studied

Sponsors

Trials by country register

How this page is built